Introduction
Accelerated atherosclerosis and vascular calcification (VC) greatly contribute to the morbidity and mortality of patients with chronic kidney disease (CKD). 1 Numerous studies have shown that VC is an active, highly regulated cellular process, mainly mediated by vascular smooth muscle cells (VSMCs). 2, 3 Among the key events involved in VC promotion, increases in extracellular calcium and phosphate levels lead to VSMCs transition from a contractile to an osteo-chondrogenic phenotype with the formation of a pro-calcifying matrix and vesicles able to nucleate hydroxyapatite. This process is also associated with loss of mineralization inhibitors, including matrix gla protein and pyrophosphate, with calcium-and phosphate-dependent cell death, production of apoptotic bodies, and development of mineral nucleation. 3 Initially cloned from parathyroid and renal tissue, respectively, the calcium-sensing receptor (CaSR) has subsequently been found to be expressed in many other tissues. Its precise role in physiological and pathological processes has since been studied in numerous laboratories. In patients with CKD, the introduction of the calcimimetic cinacalcet, an allosteric modulator of the CaSR, has proved to be one of the most effective drugs in treating secondary hyperparathyroidism (sHPT). It reduces serum parathyroid hormone (PTH), calcium and phosphorus, and thereby probably inhibits the progression of VC. 4 -6 In addition to their systemic effects, the calcimimetics also exert a direct protective effect against VC on the vessel wall. 7 Of note, the CaSR is expressed by VSMCs, 8 with lower expression in aortic tissue of CKD patients than healthy subjects. 9 In support of this finding, CaSR down-regulation was observed in VSMCs in vitro in response to elevated calcium concentrations ([Ca 2+ ]), in association with increased mineral deposition in VSMCs transfected with dominant negative CaSR. 10 These observations suggest that a pro-mineralizing environment decreases local CaSR expression, similar to that observed in parathyroid tissue of CKD patients with severe sHPT. 11 Of interest, stimulation by calcimimetics of the CaSR expressed in VSMCs delayed both phosphate-and calcium-induced mineralization in vitro, 7, 10, 12 suggesting a local protective role of the CaSR against VC. However, little is known about the processes by which calcimimetics exert such inhibitory action. The aim of the present work was to examine in more detail the role of the calcimimetics R-568 and AMG 641 in the expression of the CaSR in human VSMCs (h-VSMCs), and the consequences for cell phenotype and mineral deposition in vitro.
Methods

Isolation of h-VSMCs
H-VSMCs were isolated from human proximal ascending aortas by a modification of the explants method, 13 as detailed in Supplementary material online, Methods. Samples were obtained after aortic valve bypass surgery or other types of surgery on the aorta from patients with various cardiovascular diseases (Pr Caus, Pô le Coeur Thorax Vaisseaux, CHU Amiens, France) who gave informed written consent in accordance with French legislation, under PROTOCOL N82009-19, CPP Nord-Ouest II. This protocol does not allow access to patients' disease history. Only lesion-free segments of the proximal ascending aorta were selected for the purpose of isolating h-VSMCs. The study conforms with the Declaration of Helsinki.
h-VSMCs mineralization assay
Mineralization of the h-VSMCs monolayer (15 000 cells/well; 24-well plates) was performed using 1% FBS-containing complete DMEM supplemented with increasing [Ca 2+ ] (from 1.8 to 5.0 mmol/L) and/or calcimimetics (generously supplied by Amgen): R-568 and AMG 641 (0.1 mmol/L). Half of the culture medium was renewed every 2 days within a period of 14 days of treatment. Detection and quantification of mineralization were performed using an adaptation of the protocol described by Stanford et al., 14 as detailed in Supplementary material online, Methods.
Flow cytometry analysis
After adequate treatment, h-VSMCs were detached using cell dissociation solution (Sigma 
H-VSMCs transfection
The design and synthesis of CaSR siRNA was carried out in collaboration with Eurogentec (Liège, Belgium) based on the reference sequence NM_000388. 
qRT-PCR
RNA isolation from h-VSMCs was performed using Tri-reagent w . Then, 1 mg of DNAse I-treated RNA was reversed transcribed into complementary DNA using the 'High Capacity cDNA Reverse Transcription Kit' according to the manufacturer's instructions (Applied Biosystems, Foster City, CA, USA). The qRT -PCR was performed on StepOnePlus real-time PCR system (Applied Biosystems) using primer sequences described in Supplementary material online, Methods and 2x SYBR green qPCR master mix (Applied Biosystems). GAPDH was used as endogenous controls for data analysis.
Statistical analysis
Experiments were performed using h-VSMCs isolated from 24 patients. The results represent at least three independent experiments each performed using cells isolated from different donors. All experiments were performed in triplicate. Results are expressed as means + SEM. Differences between groups were analysed using a non-parametric Kruskal -Wallis test. When a statistical significance (P , 0.05) was observed between groups, a nonparametric Mann-Whitney test was performed. A value of P , 0.05 was considered to be statistically significant. Figure S1 ). These treatments did not affect cell viability (Supplementary material online, Figure S2 ). Ca 2+ significantly increased mineral deposition in a dosedependent manner, as assessed by Alizarin red staining normalized to the total protein content ( Figure 1A and B). Chronic exposure (up to 14 days) to calcimimetics AMG 641 or R-568 in pro-calcifying conditions (medium containing 5.0 mmol/L Ca 2+ ) significantly decreased Ca 2+ -dependent mineral deposition of h-VSMCs by 90% ( Figure 1A and B).
To determine whether calcimimetics modulate extracellular matrix formation, type 1 collagen expression was assessed in the h-VSMC extracellular matrix by immunocytochemistry after 14 days of treatment in the pro-mineralizing condition. Chronic exposure to increasing [Ca 2+ ] dose-dependently increased the formation of an extracellular matrix rich in type I collagen ( Figure 1A ). In this pro-calcifying environment, exposure to AMG 641 or R-568 slowed type I collagen-matrix formation ( Figure 1A ). Interestingly, calcimimetics modulated neither MMP2 expression nor secretion (Supplementary material online, Figure S3 ).
To examine the effect of calcimimetics on the h-VSMCs phenotype, we evaluated SMMHC expression by immunocytochemistry. Long-term exposure to increasing [Ca 2+ ] progressively decreased SMMHC expression in the presence or absence of calcimimetics AMG 641 or R-568 ( Figure 1A) . These results were confirmed by qRT-PCR ( Figure 1C ). To confirm these results, a-actin expression was assessed by immunocytochemistry and flow cytometry. Confirming our observations, the results presented in Supplementary material online, Figure S4 show Figure S5 ).
Down-regulation of the CaSR enhances matrix formation and h-VSMCs mineralization
To confirm the implication of the CaSR in h-VSMCs mineralization, and to discriminate between CaSR-mediated and CaSR-independent Ca 2+ effects (occurring for instance through ion channels), CaSR expression was targeted using an siRNA approach. Controls of transfection efficiency are presented in Supplementary material online, Figure S6 . Blocking CaSR expression in pro-calcifying conditions significantly enhanced mineral deposition in h-VSMCs by 2.5 times when compared with scrambled siRNA-transfected cells (Figure 2A and B) . Of note, in h-VSMCs exposed to AMG 641 or R-568 in pro-calcifying conditions, CaSR down-regulation by siRNA increased cell mineralization by three and two times, respectively, compared with scrambled siRNA (Figure 2A and B) .
In pro-calcifying conditions, there was also an increase of type I collagen content over the cells transfected with CaSR siRNA compared with scrambled siRNA ( Figure 2B ). In h-VSMCs exposed to calcimimetics, the down-regulation of CaSR expression by CaSR siRNA increased the formation of a matrix rich in type I collagen when compared with scrambled siRNA-transfected cells ( Figure 2B ).
Exposure to calcimimetics AMG 641 and R-568 increases type I collagen expression
As calcimimetics decreased the formation of a matrix rich in type I collagen, we hypothesized that CaSR activation reduces type I collagen synthesis in h-VSMCs. Therefore, h-VSMCs were exposed for 2 days to increasing [Ca 2+ ] (from 1.8 to 5.0 mmol/L) alone or in combination with either AMG 641 or R-568 at 0.1 mmol/L. qRT -PCR and western blot analyses were used to evaluate type I collagen expression. Exposure to calcimimetics did not affect type I collagen mRNA expression ( Figure 3A) , while an increase in type I collagen protein was observed ( Figure 3B ). Figure S8 to show changes in peak patterns. Exposure to increasing [Ca 2+ ] significantly decreased both total CaSR content ( Figure 4B and C) and surface CaSR expression ( Figure 4E and F ) in a concentration-dependent manner at both 2 and 14 days of exposure. Interestingly, no effect on either total or surface CaSR expression was observed after only 1 day of exposure in response to increasing [Ca 2+ ] (Figure 4A and D) .
Of note, exposure to calcimimetics AMG 641 or R-568 for 1 day in the presence of 1.8 mmol/L Ca 2+ increased the net CaSR content by 40% compared with control condition (1.8 mmol/L Ca 2+ ) ( Figure 4A ). This increase was maintained after 2 days and reached 50% after 14 days ( Figure 4B and C ) . No effect on cell surface expression was observed after 1 day exposure to AMG 641 or R-568 ( Figure 4D) . In same conditions, exposure for 2 or 14 days led to an increase in surface CaSR expression of 20 and 30% and 35 and 40%, respectively ( Figure 4E and F ) .
To determine in which proportion the expression of the CaSR was modulated by calcimimetics during mineral development, h-VSMCs were incubated for 1, 2, or 14 days with 0.1 mmol/L of calcimimetics AMG 641 or R-568 in pro-calcifying conditions (5.0 mmol/L Ca 2+ ). Exposure to calcimimetics for 2 days maintained total CaSR levels similar to control condition (1.8 mmol/L Ca 2+ ) by promoting a 45% increase in its expression compared with treatment in high-Ca 2+ medium alone, thus inhibiting the Ca 2+ -dependent decrease of the total CaSR content ( Figure 4B) . A similar effect was found in h-VSMCs treated for 14 days with AMG 641 in pro-mineralizing conditions, whereas no difference was observed with R-568 ( Figure 4D ). Of interest, treating h-VSMCs for 2 days with AMG 641 or R-568 in pro-calcifying conditions also maintained CaSR levels on cell surface similar to control conditions (1.8 mmol/L Ca 2+ ), by significantly increasing its expression by 25 and 40%, respectively, compared with high-Ca 2+ medium alone, which significantly inhibited the Ca 2+ -dependent decrease of the surface CaSR content ( Figure 4E ). Of note, both calcimimetics reversed the Ca 2+ -dependent decrease of surface CaSR expression at day 14, by enhancing it by 10 and 25%, respectively, compared with exposure to 5.0 mmol/L Ca 2+ alone. Interestingly, under these culture conditions R-568 still maintained the CaSR content on the cell surface similar to control condition, while the effect of AMG 641 was significantly reduced ( Figure 4F ).
Exposure to calcimimetics enhances de novo CaSR protein synthesis as well as CaSR export and maturation to the plasma membrane in h-VSMCs
To determine whether the induction of CaSR protein expression by calcimimetics requires de novo protein synthesis, CaSR mRNA expression was evaluated using qRT-PCR. Exposure to CaSR agonists, either Ca 2+ , AMG 641 or R-568, significantly increased relative CaSR mRNA levels ( Figure 5A ). To confirm these results, h-VSMCs were treated with 10 mmol/L cycloheximide (CHX), an inhibitor of protein synthesis, for 2 days in the presence or absence of calcimimetics (0.1 mmol/L). Exposure to CHX significantly decreased CaSR expression by 25% compared with control condition (1.8 mM Ca 2+ ). It also inhibited both AMG 641-and R-568-dependent increases in CaSR protein expression by 50 and 30%, respectively ( Figure 5B ). To elucidate how calcimimetics increase surface CaSR expression, cells were treated for 2 days with 0.01 mmol/L of brefeldin A (BFA), an inhibitor of protein transport from the endoplasmic reticulum (ER) to the Golgi apparatus, in the presence or absence of calcimimetics (0.1 mmol/L). Treating h-VSMCs with BFA significantly decreased surface CaSR expression by 18% compared with control condition (1.8 mM Ca 2+ ). Of interest, exposure to BFA partially inhibited both AMG 641-and R-568-dependent increases of surface CaSR expression by 28% ( Figure 5C ). Knowing that glycosylation is a major step of CaSR maturation, h-VSMCs were treated for 2 days with 0.04 mmol/L of tunicamycin (TUNICA), an inhibitor of glycosylation. Treating h-VSMCs with TUNICA significantly decreased surface CaSR expression by 28% when compared with control condition (1.8 mM Ca 2+ ). Of interest, exposure to TUNICA completely inhibited both AMG 641-and R-568-dependent increases of surface CaSR expression by 55 and 49%, respectively ( Figure 5C ). In these experiments, DMSO, which was the vehicle used to prepare BFA and TUNICA, did not modulate CaSR expression. Flow cytometry histograms relative to 
Discussion
Apart from the cationic substances that function as CaSR agonists, calcimimetics as synthetic CaSR modulators have been developed to manage hyperparathyroidism and related disorders of calcium metabolism. 15 Among them, R-568 and AMG 641 have been largely studied in recent years. In experimental studies, both calcimimetics were shown to reduce high-serum PTH in uraemic rats with sHPT without increasing serum calcium or phosphorus, in contrast to active vitamin D sterols, thereby preventing the development of extraskeletal calcification. 16 R-568 was also shown to delay the progression of both aortic calcification and atherosclerosis in uraemic, apolipoprotein E-deficient mice. 7 In chronic haemodialysis patients with sHPT, the calcimimetic cinacalcet delays the progression of vascular and valvular calcification. 4 Although these effects are generally ascribed to a better control of serum PTH, calcium, and phosphorus, recent in vitro and in vivo studies also suggest a direct action on the vessel wall, inhibiting vascular mineralization through CaSR activation in VSMCs. 7, 10 In the present study, we confirm that both R-568 and AMG 641 decrease h-VSMCs calcification in vitro when cultured in the presence of high [Ca 2+ ]. In these culture conditions, transfection with a siRNAblocking CaSR expression enhances mineral deposition, supporting the hypothesis that direct CaSR activation in vascular cells slows the calcification process. This would also be compatible with the suggestion made previously 17 that apart from direct stimulation of mineral deposition, the Ca 2+ ion could also limit this process by activating the CaSR in h-VSMCs. Thus, the calcimimetics may enhance the process further by sensitizing the receptor to Ca 2+ . As shown in Supplementary material online, Figure S6D , the transfection process delayed cell mineralization, thus all data obtained after transfection with CaSR siRNA were compared with scrambled-transfected cells.
VC is an active, cell-mediated process which has similarities with endochondral ossification. 18 It involves osteo-chondrogenic differentiation of VSMCs, characterized by down-regulation of smooth muscle (SM) lineage gene expression and up-regulation of osteo/chondrogenic gene expression (RunX2, ALP, OPN), 3,19 -21 leading to bone matrix protein deposition. 22 Herein, we demonstrate that long-term exposure of h-VSMCs to AMG 641 or R-568 does not modulate SMMHC, RunX2, ALP, or OPN mRNA expressions, but prevents from Ca 2+ -dependent loss of a-actin, which might contribute to the maintenance of a contractile phenotype. This protective effect was partially abolished by transfection of h-VSMCs with a CaSR siRNA, demonstrating the involvement of the CaSR in this process. Interestingly, in pro-calcifying conditions incubation with either AMG 641 or R-568 does not affect type I collagen mRNA expression, but increases protein expression, and reduces type I collagen development outside the cells. In light of these data, we hypothesized that calcimimetics can protect h-VSMCs from mineral deposition by reducing type I collagen secretion. In this case, the collagen which is not secreted accumulates in the cells, which explains the increase in the protein level. This protective effect is partially abolished by transfection of h-VSMCs with a CaSR siRNA. Calcimimetics have also been shown to prevent VC by down-regulating the expression of the calcification-promoting sodium-phosphate co-transporter PiT-1, and by decreasing the vascular expression of bone morphogenetic protein-2. 12, 23 These observations suggest that the local protective role of calcimimetics may occur not only by acting on h-VSMCs extracellular matrix, but also on various other processes involved in VC.
As reported previously, CaSR expression is reduced in aortas harvested from CKD patients 9 and in atherosclerotic calcified arteries from non-CKD patients, 10 suggesting that the CaSR could play a pre- 10 Here, we show that and/or calcimimetics on surface CaSR expression after 1, 2, and 14 days of exposure, respectively. *P , 0.05, **P , 0.01, and ***P , 0.001 vs. Here, we demonstrate that R-568 and AMG 641 increase both total and surface CaSR content in h-VSMCs. These effects are comparable with the calcimimetic-elicited CaSR up-regulation observed in parathyroid cells of uraemic rats and patients with hyperparathyroidism.
11,23
We further show that exposure to calcimimetics in pro-calcifying conditions inhibits the Ca 2+ -dependent decrease of both net and surface
CaSR abundance in h-VSMCs. This could serve to amplify the protective signalling discussed above. 23 Our results also suggest that the up-regulation requires de novo protein synthesis, together with an increased export of CaSR protein from the ER to the plasma membrane, by favouring CaSR maturation. These data are in accordance with Grant et al., 25 who demonstrated that in HEK 293 cells the signalling properties of the CaSR result from agonist-driven maturation and insertion of CaSRs into the plasma membrane through a mechanism termed agonist-driven insertional signalling. However, from the present data, we cannot ascertain whether calcimimetics enhance CaSR expression at the plasma membrane by increasing CaSR recycling. 26 This issue requires further study. In this work, all samples were isolated from lesion-free segments of the proximal ascending aorta. Thus, the observed variability of CaSR expression should mainly reflect interindividual differences. Nevertheless, a possible limitation of our study is that an influence of each patient's underlying cardiovascular disease cannot be excluded.
In conclusion, the present experiments demonstrate that h-VSMCs express a functional CaSR, whose activation appears to play a major role in the regulation of h-VSMC mineralization. Our finding that longterm exposure to calcimimetics inhibits the Ca 2+ -dependent decrease of the net and surface CaSR content indicates that not only enhanced activation, but also increased biosynthesis of the CaSR, its maturation, and its transfer from the ER to the plasma membrane are involved in this action, resulting in reduced matrix secretion and mineral deposition ( Figure 6 ). These observations suggest that apart from their systemic effects on serum PTH, calcium, and phosphorus levels calcimimetics 
Supplementary material
Supplementary material is available at Cardiovascular Research online. The local activation of the CaSR by the calcimimetics enhances its own expression and favours CaSR maturation and export to the plasma membrane. This calcimimetic-dependent overexpression of the CaSR could amplify the protective effects of CaSR activation on mineral deposition. HAP, hydroxyapatite. SMMHC, smooth muscle myosin heavy chain. ER, endoplasmic reticulum.
